Wanted, dead or alive: New viral vaccines

被引:47
作者
Amanna, Ian J. [2 ]
Slifka, Mark K. [1 ]
机构
[1] Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Beaverton, OR 97006 USA
[2] Najit Technol Inc, Portland, OR 97201 USA
关键词
Immunological memory; T cell; B cell; Antibody; Vaccine; Virus; YELLOW-FEVER VACCINE; SEVERE COMBINED IMMUNODEFICIENCY; ANTIBODY-BASED THERAPIES; ORAL CHOLERA VACCINES; SMALLPOX VACCINE; GAMMA-GLOBULIN; HIV-1; VACCINE; POLIOVIRUS VACCINE; HUMORAL IMMUNITY; KILLED VACCINE;
D O I
10.1016/j.antiviral.2009.08.008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Vaccination is one of the most effective methods used for protecting the public against infectious disease. Vaccines can be segregated into two general categories: replicating vaccines (i.e., live, attenuated vaccines) and non-replicating vaccines (e.g., inactivated or subunit vaccines). It has been assumed that live attenuated vaccines are superior to non-replicating vaccines in terms of the quality of the antiviral immune response, the level of protective immunity, and the duration of protective immunity. Although this a prevalent viewpoint within the field, there are several exceptions to the rule. Here, we will explore the historical literature in which some of these conclusions have been based, including "Experiments of Nature" and describe examples of the efficacy of replicating vaccines compared to their non-replicating counterparts. By building a better understanding of how successful vaccines work, we hope to develop better "next-generation" vaccines as well as new vaccines against HIV-a pathogen of global importance for which no licensed vaccine currently exists. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:119 / 130
页数:12
相关论文
共 128 条
  • [51] Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies
    Haigwood, NL
    Montefiori, DC
    Sutton, WF
    McClure, J
    Watson, AJ
    Voss, G
    Hirsch, VM
    Richardson, BA
    Letvin, NL
    Hu, SL
    Johnson, PR
    [J]. JOURNAL OF VIROLOGY, 2004, 78 (11) : 5983 - 5995
  • [52] Duration of antiviral immunity after smallpox vaccination
    Hammarlund, E
    Lewis, MW
    Hansen, SG
    Strelow, LI
    Nelson, JA
    Sexton, GJ
    Hanifin, JM
    Slifka, MK
    [J]. NATURE MEDICINE, 2003, 9 (09) : 1131 - 1137
  • [53] Hammitt Laura L, 2008, J Infect Dis, V198, P1776, DOI 10.1086/593335
  • [54] Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge
    Hansen, Scott G.
    Vieville, Cassandra
    Whizin, Nathan
    Coyne-Johnson, Lia
    Siess, Don C.
    Drummond, Derek D.
    Legasse, Alfred W.
    Axthelm, Michael K.
    Oswald, Kelli
    Trubey, Charles M.
    Piatak, Michael, Jr.
    Lifson, Jeffrey D.
    Nelson, Jay A.
    Jarvis, Michael A.
    Picker, Louis J.
    [J]. NATURE MEDICINE, 2009, 15 (03) : 293 - 299
  • [55] Clinical case definitions for Argentine hemorrhagic fever
    Harrison, LH
    Halsey, NA
    McKee, KT
    Peters, CJ
    Oro, JGB
    Briggiler, AM
    Feuillade, MR
    Maiztegui, JI
    [J]. CLINICAL INFECTIOUS DISEASES, 1999, 28 (05) : 1091 - 1094
  • [56] Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques
    Hessell, Ann J.
    Poignard, Pascal
    Hunter, Meredith
    Hangartner, Lars
    Tehrani, David M.
    Bleeker, Wim K.
    Parren, Paul W. H. I.
    Marx, Preston A.
    Burton, Dennis R.
    [J]. NATURE MEDICINE, 2009, 15 (08) : 951 - U155
  • [57] A yellow fever vaccine.
    Hindle, E
    [J]. BRITISH MEDICAL JOURNAL, 1928, 1928 (01): : 976 - 977
  • [58] Comparative analysis of titers of antibody against measles virus in sera of vaccinated and naturally infected Japanese individuals of different age groups
    Itoh, M
    Okuno, Y
    Hotta, H
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (05) : 1733 - 1738
  • [59] JANEWAY CA, 1945, B NEW YORK ACAD MED, V21, P202
  • [60] Jenner E., 1799, FURTHER OBSERVATIONS